Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Multi-center Open-label Controlled Trial of Comparison 3 vs 12 Months of Dual Anti-Platelet Therapy After Implantation of Firehawk Sirolimus Target- Eluting Stent in Patients With Stable Coronary Artery Disease

NCT03008083 is registered in ClinicalTrials.gov with Shanghai MicroPort Medical (Group) Co., Ltd. as lead sponsor.

NCT NCT03008083
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03008083 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Multi-center Open-label Controlled Trial of Comparison 3 vs 12 Months of Dual Anti-Platelet Therapy After Implantation of Firehawk Sirolimus Target- Eluting Stent in Patients With Stable Coronary Artery Disease
Lead sponsor
Shanghai MicroPort Medical (Group) Co., Ltd.
Phase
Phase 4
Overall status
Unknown status
Start date
January 10, 2019
Completion date
October 31, 2022
Enrollment
2,446 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

drug-eluting stents, percutaneous coronary intervention